Towards new tuberculosis drugs

被引：20

作者：

Cole, S. T.

Alzari, P. M.

机构：

[1] Ecole Polytech Fed Lausanne, Global Hlth Inst, CH-1015 Lausanne, Switzerland

[2] Inst Pasteur, Unite Biochim Struct, F-75724 Paris 15, France

来源：

BIOCHEMICAL SOCIETY TRANSACTIONS | 2007年 / 35卷

关键词：

directly observed therapy short course (DOTS); moxifloxacin; PA-824; R207910; serine/threonine kinase; SQ109;

D O I：

10.1042/BST0351321

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The need for better drugs to treat tuberculosis has never been greater. Despite insufficient funding for discovery research, intensive efforts have been made to find and develop new lead compounds capable of reducing the duration of the present treatment known as DOTS (directly observed therapy short course), from 6 to under 4 months. This minireview describes the progress achieved during the last 5 years and highlights some of the successes without neglecting the problems.

引用

收藏

页码：1321 / 1324

页数：4

相关论文

共 43 条

[1] Antimycobacterial activity of econazole against multidrug-resistant strains of Mycobacterium tuberculosis [J].

Ahmad, Zahoor ;

Sharma, Sadhna ;

Khuller, G. K. ;

Singh, Pushpendra ;

Faujdar, Jaya ;

Katoch, V. M. .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2006, 28 (06) :543-544

[2] A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis [J].

Andries, K ;

Verhasselt, P ;

Guillemont, J ;

Göhlmann, HWH ;

Neefs, JM ;

Winkler, H ;

Van Gestel, J ;

Timmerman, P ;

Zhu, M ;

Lee, E ;

Williams, P ;

de Chaffoy, D ;

Huitric, E ;

Hoffner, S ;

Cambau, E ;

Truffot-Pernot, C ;

Lounis, N ;

Jarlier, V .

SCIENCE, 2005, 307 (5707) :223-227

[3] The eukaryotic-like Ser/Thr protein kinases of Mycobacterium tuberculosis [J].

Av-Gay, Y ;

Everett, M .

TRENDS IN MICROBIOLOGY, 2000, 8 (05) :238-244

[4] Foreword from the co-editor-in-chief [J].

Brennan, PJ .

TUBERCULOSIS, 2001, 81 (1-2) :1-1

[5] Peripheral neuropathy associated with prolonged use of linezolid [J].

Bressler, AM ;

Zimmer, SM ;

Gilmore, JL ;

Somani, J .

LANCET INFECTIOUS DISEASES, 2004, 4 (08) :528-531

[6] Glivec (ST1571, Imatinib), a rationally developed, targeted anticancer drug [J].

Capdeville, R ;

Buchdunger, E ;

Zimmermann, J ;

Matter, A .

NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (07) :493-502

[7] Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro [J].

Chen, Ping ;

Gearhart, Jackie ;

Protopopova, Marina ;

Einck, Leo ;

Nacy, Carol A. .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 58 (02) :332-337

[8] Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence [J].

Cole, ST ;

Brosch, R ;

Parkhill, J ;

Garnier, T ;

Churcher, C ;

Harris, D ;

Gordon, SV ;

Eiglmeier, K ;

Gas, S ;

Barry, CE ;

Tekaia, F ;

Badcock, K ;

Basham, D ;

Brown, D ;

Chillingworth, T ;

Connor, R ;

Davies, R ;

Devlin, K ;

Feltwell, T ;

Gentles, S ;

Hamlin, N ;

Holroyd, S ;

Hornby, T ;

Jagels, K ;

Krogh, A ;

McLean, J ;

Moule, S ;

Murphy, L ;

Oliver, K ;

Osborne, J ;

Quail, MA ;

Rajandream, MA ;

Rogers, J ;

Rutter, S ;

Seeger, K ;

Skelton, J ;

Squares, R ;

Squares, S ;

Sulston, JE ;

Taylor, K ;

Whitehead, S ;

Barrell, BG .

NATURE, 1998, 393 (6685) :537-+

[9] Prospects for new antitubercular drugs [J].

Duncan, K ;

Barry, CE .

CURRENT OPINION IN MICROBIOLOGY, 2004, 7 (05) :460-465

[10] Global epidemiology of tuberculosis [J].

Dye, C .

LANCET, 2006, 367 (9514) :938-940

← 1 2 3 4 5 →